Labcorp Holdings (LH, Health Care Services) Stock Valuation & Fair Value Mixed on our tests
Labcorp Holdings (LH, Health Care Services) trades at a blended P/E of 17.2, about 17% above its historical normal valuation, with a forward growth estimate of 8.9% and a PEG of 1.93. Analysts' one-year estimates have been hit 64% of the time. Priced at its historical normal P/E of 14.8 on the same blended earnings, the 2026-10-02 close of $308.49 corresponds to about $264 a share. This is a valuation reference, not a price target.
- Price $314.20 at the 2026-10-08 close, 0.4% above the 20-day average ($313.00) and 1.7% below the 50-day ($319.61).
- RSI (14) at 50.5.
- 52-week range $244.17 to $338.61: the price is 7.2% below the high and 28.7% above the low.
The Street vs SeerForecast
Wall Street's mean price target for LH is $344.81 across 16 analysts, 9.7% above the current price. The average analyst rating is Buy. Our SeerForecast read of the same stock, formed without analyst targets: mixed on our tests. When the two disagree, start your digging there.
Valuation flags
- No notable valuation flags.
Verdict history
tickerseer's rating has been mixed on our tests since 2026-06-03.
Not every point was recorded live. Points marked recalculated apply today's valuation rules to the metrics tickerseer archived that week.
Selected weeks: the first, the latest, every week the rating moved, and the cheapest and dearest.
Show all 37 weeks
Frequently asked questions
Is Labcorp Holdings stock overvalued?
At a blended P/E of 17.2 versus its historical normal P/E of 14.8, Labcorp Holdings trades about 17% above its typical valuation, with a PEG of 1.93 on 8.9% forward growth. tickerseer currently rates it mixed on our tests.
What is Labcorp Holdings's fair value and PEG?
Labcorp Holdings trades at a blended P/E of 17.2 against a historical normal P/E of 14.8, a PEG of 1.93, and a forward growth estimate of 8.9%. Priced at its historical normal P/E of 14.8 on the same blended earnings, the 2026-10-02 close of $308.49 corresponds to about $264 a share. This is a valuation reference, not a price target.
Has tickerseer's rating of Labcorp Holdings changed?
tickerseer's rating has been mixed on our tests since 2026-06-03.
What is the analyst price target for Labcorp Holdings?
The mean Wall Street price target for Labcorp Holdings is $344.81 across 16 analysts, 9.7% above the current price. tickerseer's SeerForecast verdict is formed independently of analyst targets.
Industry: Health Care Services. Create a free account to see the full analysis: the SeerAI score, its five quality sub-scores, valuation history, and the AI research note. Options setups and metric history are part of the paid plans.
Get the free weekly earnings preview
One email each Monday with the week's named earnings setups, the reasoning, and what settled last week. Strikes and sizing stay in Premium.
It's free, and you can unsubscribe any time. We also send a short product update once a month. Educational content, not investment advice.